medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

# Postlockdown Dynamics of COVID-19 in New York, Florida, Arizona, and Wisconsin

Sherry Scott[3], Keisha J. Cook[2], Kamal Barley[1]

*Department of Mathematics, formerly MSOE, Department of Mathematics, Tulane University. Applied Mathematics Statistics, Stony Brook University.*

**Abstract**

The COVID-19 pandemic is widely studied as it continues to threaten many populations of people especially in the USA, the leading country in terms of both deaths and cases. More and more reports show that the spread of COVID-19 involves infected individuals first passing through a pre-symptomatic infectious stage in addition to the incubation period and that many of the infectious individuals are asymptomatic. In this study, we design and use a mathematical model to primarily address the question of who are the main drivers of COVID-19 - the symptomatic infectious or the presymptomatic and asymptomatic infectious in the states of Florida, Arizona, New York, Wisconsin and the entire United States. We emphasize the benefit of lockdown by showing that for all four states, earlier and later lockdown dates decrease the number of cumulative deaths. This benefit of lockdown is also evidenced by the decrease in the infectious cases for Arizona and the entire US when lockdown is implemented earlier. When comparing the influence of the symptomatic infectious versus the presympomatic/asymptomatic infectious, it is shown that, in general, the larger contribution comes from the latter group. This is seen from several perspectives (1) in terms of daily cases, (2) in terms of daily cases when the influence of one group is targeted over the other by setting the effective contact rate(s) for the non-targeted group to zero, and (3) in terms of cumulative cases and deaths for the US and Arizona when the influence of one group is targeted over the other by setting the effective contact rate(s) for the non-targeted group to zero. The consequences of the difference in the contributions of the two infectious groups is simulated in terms of testing and these simulations show that an increase in testing and isolating for the presymptomatic and asymptomatic infectious group has more impact than an increase in testing for the symptomatic infectious. For example, for the entire US, a 50% increase in testing for the presymptomatic and asymptomatic infectious group results in a 35% decrease in deaths as opposed to a lower 6% decrease in deaths when a 50% increase in testing rate for the symptomatic infectious is implemented. We also see that if the testing for infectious symptomatic is kept at the baseline value and the testing for the presymptomatic and asymptomatic is increased from 0.2 to 0.25, then the control reproduction number falls well below 1. On the other hand, to get even close to such a result when keeping the presymptomatic and asymptomatic at baseline fitted values, the symptomatic infectious testing rate must be increased considerably more - from 0.25 to 1.7. Lastly, we use our model to simulate an implementation of a natural herd immunity strategy for the entire U.S. and for the state of Wisconsin (the most recent epicenter) and we find that such a strategy requires a significant number of deaths and as such is questionable in terms of success. We conclude with a brief summary of our results and some implications regarding COVID-19 control and mitigation strategies.

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

*Keywords:* COVID-19, symptomatic infectious, asymptomatic infectious, presymptomatic infectious, natural herd immunity

## 1. Introduction

The coronavirus, known as COVID-19, emerged in Wuhan, China in December 2019, and has since then spread to all countries on earth. As of 12/10/2020, the United States has reported 15,535,565 cases and 291,403 deaths and although the leading country in both deaths and cases, the U.S. did not implement a national pandemic control initiative. Instead, many states and cities implemented their own initiatives at various times, and the transmission of COVID-19 has varied from state to state. States also implemented

[1]Email: Kamal.Barley@stonybrook.edu
[2]Email: kcook7@tulane.edu
[3]Email: sscott@msri.org, corresponding author
[4]This collaboration was sponsored by the ADJOINT 2020 workshop at MSRI through the University of California Berkeley.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

their own testing initiatives. Around 12-10-2020, the reported testing rates are as follows: Arizona testing at a rate of 347.7 tests per 100,000 people, Florida testing at a rate of 497.2 tests per 100,000 people, New York testing at a rate of 985.7 tests per 100,000 people, and Wisconsin testing at a rate of 562.4 tests per 100,000 people [2]. With regard to mask usage, the observed mask usage percentage in the US has increased since the beginning of the pandemic. From March 1, 2020 to May 1, 2020, the mask use percentage increased from 5% to 40%. From May 1, 2020 to November 22, 2020, the mask use percentage increased from 71%. Social distancing has also played a role in the transmission of COVID-19. On March 8, 2020 to April 4, 2020, the US experienced a 53% decrease in mobility. From April 4, 2020 to June 24, 2020, the decrease in mobility changed to only -22%. From June 24, 2020 to November 22, 2020, the mobility oscillated between -18% and -25% [3]. The social distancing statistics are due to the fact that different states implemented stay-at-home periods for various intervals of time. All of these factors play a part in the transmission of COVID-19 in the US as a whole, and effectively in each state. Although we do not consider all of these measures directly, we do discuss the effect that lockdown has on the number of cases and deaths. We do include mask usage, and we use a different mask compliance value for each period per state [10]. To study social distancing, we fit the values for the effective contact rate for each time period per state and per time period.

Mathematical modelling can help us better understand how COVID-19 cases and mortality is affected based on when and how long lockdown periods are enforced. Modelling can also help us identify the main drivers of the disease and give insight on how best to use the standard control and mitigation strategies. We expand on the standard SIR model, which uses a system of ordinary differential equations to model disease spread through multiple compartments over time. In this study, we do not consider a time-varying system.

Prior studies consider susceptible individuals transitioning to exposed and then to infectious. We include a presymptomatic compartment for individuals who are infectious before the onset of symptoms. We also consider individuals who were tested, resulting in an asymptomatic or symptomatic classification, as well as the population of people who may have self-isolated after being exposed by an infected individual. It is known that over the course of the pandemic, hospitals have been highly stressed and over-crowded due to the influx of COVID-19 patients. In order to study mortality due to the pandemic, we also include compartments that keep track of the number of patients admitted to the hospital and the ICU.

We explore scenarios where lockdown is started earlier or extended past the reported date. We show that both scenarios decrease the number of deaths. We can use these type of simulations to predict future mortality populations and use the information to help with determining when lockdown periods should start and how long the lockdown period should be enforced.

Finally, in response to the increase in public discussions of a natural herd immunity approach, we use our model to run some basic scenarios for implementing such a strategy in the state of Wisconsin and the US as a whole. We simulate the number of deaths that would occur before herd immunity is achieved.

## 2. Main Questions

The overall purpose of this study is to explore the postlockdown dynamics of COVID-19 and in the process, explore the notion that the main drivers of COVID19 are the asymptomatic and presymptomatic infectious individuals. Because both the asymptomatic and presymptomatic infectious spread COVID-19 without showing symptoms we group these two compartments together and compare that group to the symptomatic infectious. More specifically, we use a mathematical model to address the following questions for New York, Arizona, Florida, Wisconsin, and in some cases, the entire US. The section of the paper in which each question is addressed is given after the question.

- How do changes in lockdown dates (i.e., earlier or later lockdown dates) affect the number of deaths and cases? (Section 4.3.1)
- How does the contribution of the presymptomatic and asymptomatic infectious individuals compare to that of the symptomatic infectious in terms of cases and deaths? (Section 4.3.2)

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- If we isolate all symptomatic infectious individuals or all asymptomatic and presymptomatic infectious individuals, how will this impact deaths and cases? (Section 4.3.3)
- How might a minimum testing rate for presymptomatic and asymptomatic compare to that for the symptomatic infectious individuals in order to obtain a reproduction number below 1? (section 4.3.4)
- How many deaths will occur in a natural herd immunity simulation for Wisconsin and the entire US? (Section 4.4)

### *2.1. COVID-19*

In order to assess and deliver guidelines for individuals to avoid coronavirus infection, the CDC has implemented models equipped with the many stages of the virus [1]. A person who has been infected is considered pre-symptomatic (an individual who is infectious but did not show symptoms at the time of testing) or asymptomatic (a person who is infectious and does not show symptoms throughout the course of the infection). The CDC built pandemic planning scenarios varying the infectiousness of asymptomatic individuals compared to symptomatic, varying the percent of asymptomatic individuals, and varying the percentage of transmission of presymptomatic individuals. In this paper, we use similar methods to build our model and determine parameter values for the locations and time periods of interest. Figure 1 shows the stages of COVID-19, especially the incubation period, infectious period, presymptomatic period, and symptomatic period. It should be noted that a presymptomatic infectious individual can become either asymptomatic or symptomatic infectious.




Figure 1: The Stages of COVID-19

We are interested in modeling COVID-19 in the United States as a whole, as well as focusing on four states. We consider New York (Northeast), which started as an epicenter in the US. We consider Florida (Southeast) and Arizona (Southwest) due to the fact that they became hot spots with significant numbers of daily cases and overwhelming numbers in their healthcare facilities. Lastly, we consider Wisconsin (Midwest), which became a hot spot later in the year. Table 1 shows the differences between the states with regards to the number of cumulative deaths.

Cumulative Deaths

| | Beginning of lockdown | End of lockdown | on August 11, 2020 | on November 23, 2020 |
|---|---|---|---|---|
| United States | 16767 | 104803 | 164519 | 257779 |
| Arizona | 25 | 651 | 4199 | 6464 |
| Florida | 170 | 1399 | 8553 | 18085 |
| New York | 249 | 30482 | 32770 | 34339 |
| Wisconsin | 10 | 594 | 1006 | 3158 |

Table 1: This table gives the cumulative deaths for each state and the United States. The lockdown dates depend on the state.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

## 3. Methods

### *3.1. Model with presymptomatic compartment and face masks*

We use a modified Kermack-McKendrik-type epidemic (no human demography) model to better understand the dynamics of COVID-19. Since a main objective of this study is to analyze the role of infectious individuals who show no symptoms, the model (2) includes a presymptomatic compartment as the foundation for parameter estimation. We use a deterministic susceptible, exposed, presymptomatic, symptomatically-infectious, asymptomatically-infectious, self-isolated, hospitalized, recovered, and ICU patients modeling framework, with the classes denoted as $S(t)$, $E(t)$, $E_P(t)$, $I(t)$, $A(t)$, $J(t)$, $H(t)$, $R(t)$,$C(t)$ respectively; we also include $D(t)$ to track deaths.The model also includes the mitigation/control interventions of face mask usage (with a compliance parameter as well as a face mask efficacy parameter) and testing/detection implementation for each of the infectious classes.




Figure 2: Schematic flow diagram of the model

### *3.2. Data Collection*

We obtain the observed cumulative deaths and cases data for the states of Arizona, Florida, New York and Wisconsin from the COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (2020). The repository contains data beginning at January 22, 2020 (the marked beginning of the pandemic in the US), however, we focus primarily on the data from March 1, 2020 through October 13, 2020. Using these data sets we determine the initial conditions for the number of cases and deaths for a given time period.

The model has 24 parameters and we use values from the literature for 18 of these and estimate the remaining 6 by fitting the model to the observed cumulative mortality data for each state. The parameters that are estimated are as follows: the effective contact rate for the symptomatically-infectious individuals $\beta_I$, the effective contact rate for the asymptomatically-infectious individuals $\beta_A$, the effective contact rate for presymptomatically-infectious individuals $\beta_P$, the rate at which presympotomatically-infectious individuals self-isolate $\tau_P$, the rate at which asympotomatically-infectious individuals self-isolate $\tau_A$, and the hospitalization rate for self-isolating individuals $\alpha_J$. Parameter fitting was performed using a non-linear sum-of-squares estimate - i.e. determining the best parameters set that minimizes the sum of the square of the difference between the model outputs for death and the observed values for deaths.

Our model for the transmission dynamics of COVID-19 is given by the following deterministic system of non-linear differential equations.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

$$
\begin{aligned}
\frac{dS}{dt} &= -\beta_I(1-\epsilon_m c_m)\frac{SI}{N} - \beta_A(1-\epsilon_m c_m)\frac{SA}{N} - \beta_P(1-\epsilon_m c_m)\frac{SE_P}{N} = -\lambda S \\
\frac{dE}{dt} &= \beta_I(1-\epsilon_m c_m)\frac{SI}{N} + \beta_A(1-\epsilon_m c_m)\frac{SA}{N} + \beta_P(1-\epsilon_m c_m)\frac{SE_P}{N} - \sigma_e E = \lambda S - \sigma_e E \\
\frac{dE_P}{dt} &= \sigma_e E - \sigma_p E_P - \tau_p E_P \\
\frac{dI}{dt} &= r\sigma_p E_P - \alpha_I I - \tau_I I - \gamma_I I - \delta_I I \\
\frac{dA}{dt} &= (1-r)\,\sigma_p E_P - \alpha_A A - \tau_A A - \gamma_A A - \delta_A A \\
\frac{dH}{dt} &= \alpha_I I + \alpha_A A + \alpha_J J - \psi_H H - \gamma_H H - \delta_H H \\
\frac{dC}{dt} &= \psi_H H - \gamma_C C - \delta_C C \\
\frac{dJ}{dt} &= \tau_p E_P + \tau_A A + \tau_I I - \alpha_J J - \gamma_J J \\
\frac{dR}{dt} &= \gamma_I I + \gamma_A A + \gamma_C C + \gamma_J J + \gamma_H H \\
\frac{dD}{dt} &= \delta_A A + \delta_I I + \delta_H H + \delta_C C
\end{aligned}
\tag{1}
$$

where $N(t) = S+E+EP+I+A+H+J+C+R$ is the total population at time $t$. Let $\epsilon_m$ be the efficacy of face masks to prevent transmission and acquisition of infection, $c_m$ the compliance in face mask usage in the community ($0 < c_m \leq 1$), $\sigma$ the progression rate from exposed ($E$) to infectious classes ($I$ or $A$), $r$ the fraction of exposed individuals who show clinical symptoms at the end of the incubation period, $\tau_I$ the rate self-quarantined symptomatically-infectious humans self-isolate, $\gamma_I$, $\gamma_A$, $\gamma_J$, $\gamma_H$, $\gamma_C$ the recovery rates for the subscripted population, $\psi_H$ the rate of ICU admission for hospitalized individuals, $\alpha_I$ the hospitalization rate for symptomatically-infectious individuals, $\alpha_A$ the hospitalization rate for asymptomatically-infectious individuals, $\delta_I$ the disease-induced mortality rate for symptomatically-infectious individuals, $\delta_A$ the disease-induced mortality rate for asymptomatically-infectious individuals, $\delta_H$ the disease-induced mortality rate for hospitalized individuals, $\delta_C$ the disease-induced mortality rate individuals in ICU. We assume that hospitalized individuals do not come in contact with the general population.

## 4. Results

### *4.1. Computation of Reproduction Numbers*

The basic reproduction number $\mathcal{R}_0$ is the average number of secondary infections produced when one infected individual is introduced into a host population of susceptibles. For our model's $\mathcal{R}_0$, we have $\mathcal{R}_0 = \mathcal{R}_{0A} + \mathcal{R}_{0I} + \mathcal{R}_{0P}$ where

$$\mathcal{R}_{0A} = \frac{\beta_A(1-r)}{\alpha_A + \gamma_A + \delta_A}$$

$$\mathcal{R}_{0I} = \frac{\beta_I r}{\alpha_I + \gamma_I + \delta_I}$$

and

$$\mathcal{R}_{0P} = \frac{\beta_P}{\sigma_P}.$$

The control reproduction number $\mathcal{R}_C$ is the average number of new cases generated by a typical infectious individual introduced into a host population of susceptibles with some control measures/interventions in place. Using the next generation operator method and notation found in [12] we have the following computation for the control reproduction number $\mathcal{R}_C$. If take the column vector $(E \quad E_P \quad I \quad A)$ representing the compartments of infected, we have the associated next generation matrices, $F$ and $V$, for the new infection terms and the transition terms are given respectively as

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

$$\mathcal{F} = \begin{bmatrix} 0 & (1-\epsilon_m c_m)\,\beta_P & (1-\epsilon_m c_m)\,\beta_I & (1-\epsilon_m c_m)\,\beta_A \\ 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \end{bmatrix} \quad \text{and} \quad \mathcal{V} = \begin{bmatrix} \sigma_e & 0 & 0 & 0 \\ -\sigma_e & G_1 & 0 & 0 \\ 0 & -r\sigma_P & G_2 & 0 \\ 0 & -(1-r)\,\sigma_P & 0 & G_3 \end{bmatrix}$$

where, $G_1 = \sigma_P + \tau_P$, $G_2 = \alpha_I + \gamma_I + \delta_I + \tau_I$, $G_3 = \alpha_A + \gamma_A + \delta_A + \tau_A$. $\mathcal{R}_C$ is the spectral radius of the next generation matrix given by,

$$\mathcal{R}_C = \rho\left(FV^{-1}\right) = \mathcal{R}_I + \mathcal{R}_A + \mathcal{R}_P$$

where $\mathcal{R}_I = \frac{(1-\epsilon_m c_m)\beta_I r\sigma_P}{G_1 G_2}$, $\mathcal{R}_A = \frac{(1-\epsilon_m c_m)(1-r)\beta_A\sigma_P}{G_1 G_3}$, and $\mathcal{R}_P = \frac{(1-\epsilon_m c_m)\beta_P}{G_1}$. In absence of interventions, i.e. with $\tau_I = \tau_A = \tau_P = \tau_A = \epsilon_m = c_m = 0$, we get the basic reproduction number for model (1), $\mathcal{R}_0$, as given earlier.

**Theorem 1.** *The disease-free equilibrium (DFE) of the model 1 is locally-asymptotically stable if $\mathcal{R}_C < 1$, and unstable if $\mathcal{R}_C > 1$.*

A basic implication of Theorem 1 is that in order to control the COVID-19 outbreak (to not generate more), it suffices to keep $\mathcal{R}_C < 1$.

### *4.2. Goodness of Fit*

We analyze how well our model fits the data from John Hopkins using the T-Test in *R*. The T-Test measures the difference between two sets of continuous data. We want to compare two sample means to determine if there is a statistically significant difference between the model and the data. We use a paired T-test where each vector has the same amount of entries and the values are taken from the same independent variable. The T-Test assumes that the data in each vector is normally distributed and that they have approximately equal variances. To test for normality, we use the Shapiro-Wilk Test in *R*. The null hypothesis for this test is that the values in the vector are normally distributed. If the p-value is greater than 0.05, then the distribution of the values in the vector are not significantly different from the normal distribution. I.e. we fail to reject the null hypothesis. We can visualize this using a Q-Q plot. We assume normality if all the points fall along the reference line. We then check the variances of the values in the two vectors using the standard variance equation from probability. Let the null hypothesis for the T-Test be that the difference between the two groups is 0. The T-statistic is defined as

$$T = \frac{\bar{x_1} - \bar{x_2}}{\sqrt{(s_1^2/n_1) + (s_2^2/n_2)}}.$$

We conclude that the model for each state, cumulative death population, during the lockdown period does indeed fit the data. Table 2 shows the resulting p-values of the T-Test for each state and the United States as a whole during the lockdown period. The goodness of fit plots can be found in the appendix (section 6.3) in Figures 17, 18, 19, 20, and 21.

| | Daily p-value | Daily T-statistic | Cumulative p-value | Cumulative T-statistic |
|---|---|---|---|---|
| United States | 0.9722 | 0.035037 | 0.7839 | 0.27581 |
| Florida | 0.9083 | 0.11621 | 0.4947 | 0.69165 |
| Arizona | 0.6002 | -0.52796 | 0.0004622 | 3.7845 |
| New York | 0.8781 | -0.15396 | 0.007702 | 2.749 |
| Wisconsin | 0.02353 | -2.323 | 2.2e-16 | -17.953 |

Table 2: Goodness of Fit for the T-Test. This table gives the p-values and T-statistic for each test for each state and the United States during the lockdown period. The daily column denotes the model vs the data of the daily deaths. The cumulative column denotes the model vs the data of the cumulative deaths.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### *4.3. Simulated Epidemics*

We fit our model using the cumulative and daily mortality data for Florida, Arizona, Wisconsin, and New York over the pre-lockdown, lockdown, and post-lockdown periods based on the state's respective decisions. Florida, Arizona, New York, and Wisconsin pre-lockdown period is defined from March 10, 2020 to April 3, 2020, March 21, 2020 to March 31, 2020, March 2, 2020 to March 22, 2020, and March 19, 2020 to March 25, 2020 respectively. The lockdown period is defined from April 3, 2020 to May 4, 2020, March 31, 2020 to May 15, 2020, March 22, 2020 to May 28, 2020, March 25, 2020 to May 26, 2020 respectively. For the entire US the pre-lockdown and postlockdown dates are January 22, 2020 to April 7, 2020 and April 7, 2020 to May 28, 2020, as given in [10]. The post-lockdown periods begin at the end of the prescribed lockdown period for each state and for most of our results ends on August 11, 2020. Figure 3 shows the fit for our model with the cumulative deaths data during the lockdown period.




Figure 3: Data fitting of the model using COVID-19 mortality data for the states of Florida, Arizona, New York and Wisconsin during their respective lockdown periods. The plots show the model (blue) against the data (red).

The state variables and the parameters for our model are given in the Appendix in Tables 3 and 4 respectively.

#### *4.3.1. Lockdown starting earlier or later*

For all of the states, the first lockdown (and for most states, the only lockdown so far) was implemented in the month of March. Since an earlier lockdown would have most likely prevented the disease from gaining a foothold in these areas, when we simulate an earlier lockdown, we find that the number of cumulative deaths decreases significantly for each state. This decrease occurs each time we add one week to the beginning of the lockdown period - see Figure 4.




Figure 4: **Row 1**: The cumulative deaths for each state if lockdown began 1 week earlier. **Row 2**: The cumulative deaths for each state if lockdown began 2 weeks earlier.

In general, an earlier lockdown also results in a decrease in daily cases for both the symptomatic and asymptomatic/presymptomatic compartments, as shown in the daily cases plots for Arizona and the entire US in Figure 5.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .




Figure 5: Daily cases for the asymptomatic/pre-symptomatic individuals (cyan curve) versus the symptomatic individuals (red curve) for the entire US and Arizona if **Row 1**: Lockdown began 1 week earlier and if **Row 2**: Lockdown began 2 weeks earlier.

On the other hand, if we use the original lockdown start dates but extend the lockdown periods by 2 and 4 weeks for each state, we again see a decrease in cumulative deaths as shown in Figure 6.




Figure 6: **Row 1**: The cumulative deaths for each state if lockdown was lifted 2 weeks later. **Row 2**: The cumulative deaths for each state if lockdown was lifted 4 weeks later.

These varying lockdown dates scenarios can be used to assess the efficacy of lockdowns and to guide the manner in which the lockdowns are implemented. For example, one interesting lockdown scenario is to consider what would happen if the entire U.S. implemented a lockdown during the month of December 2020 for two weeks. In order to simulate such a strategy we reduce the contact rate parameters - i.e., the betas - by 40% [7] and run the simulation forward. As shown in Figure 7 below, the simulations give that such a lockdown would result in a marked decrease in the number of deaths.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .




Figure 7: Cumulative deaths in US with lockdown in December (green) versus without lockdown (blue)

### *4.3.2. Simulations for Asymptomatic, Presymptomatic, and Symptomatic*

In this section, we focus more on comparing the contributions of the symptomatic infectious group versus the asymptomatic and presymptomatic infectious group. To this end, we first consider plotting the daily cases for the two groups against each other. In all states and time periods, we find that the number of daily cases for the asymptomatic and presymptomatic is more than the daily cases for the symptomatic as shown in the following figure.




Figure 8: The plots show the presymptomatic and asymptomatic versus symptomatic individuals for each state during their respective **Row 1**: Pre-lockdown period, **Row 2**: Lockdown period, and **Row 3**: Post-lockdown period.

The parameter $\beta_I$ represents the contacts by the symptomatically infectious individuals that could transmit the disease. By setting $\beta_I = 0$, we eliminate that transmission and focus on the effect of the presymptomatic and asymptomatic individuals. Similarly, fixing $\beta_A = \beta_P = 0$, targets the effect of the symptomatically infectious. In order to further discern the role of the asymptomatic and presymptomatic infectious versus that of the symptomatic infectious, we consider these zero contact rate scenarios in terms of the number of daily cases for all of the states and the entire U.S. In Figure 9, we show the results for the pre-lockdown and post-lockdown periods and for those periods, we again get that the larger contribution comes from the asymptomatic and presymptomatic individuals. For the lockdown period we obtain mixed results and these are considered in the appendix (Figure 16).

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .




Figure 9: The plots show the daily cases for each state with $\beta_I = 0$ (cyan curve) and with $\beta_A = \beta_P = 0$ (red curve) during their respective **Row 1**: Pre-lockdown period and **Row 2**: Post-lockdown period.

In Figure 10, we again take the $\beta_I = 0$ (green curve) versus the $\beta_A = \beta_P = 0$ (magenta curve) scenario, but here we consider the effect in terms of cumulative cases and cumulative deaths for the entire US and the state of Arizona. Both types of plots indicate that the main drivers are the asymptomatic and presymptomatic individuals.




Figure 10: The cumulative cases and deaths for the U.S. and Arizona over the respective lockdown period where **Case 1** corresponds to $\beta_I = 0$ (green curve; so focuses on the impact of asymptomatic/pre-symptomatic individuals) and **Case 2** corresponds to $\beta_A = \beta_P = 0$ (magenta curve; so focuses on the impact of symptomatic individuals)

### *4.3.3. Isolating Symptomatic and Asymptomatic/Pre-symptomatic*

Recall that the $\tau$ values give the rate for testing/detection of infected individuals and subsequent self-isolation. In this section we compare and contrast the effect of isolating the symptomatic against the effect of isolating the asymptomatic and presymptomatic by changing the appropriate $\tau$ values. For example, to address the effect of isolating symptomatic infectious individuals, we can increase the value of $\tau_I$ (the rate that symptomatically infectious individuals self-isolate) while keeping all other rates the same. We consider this scenario for the entire U.S. and find that when $\tau_I$ increases (so that the number of symptomatically infectious individuals that are self-isolated and taken out of the general population increases), the number of cumulative deaths decreases by as much as 12.5%. Alternatively, if the rate of self-isolation for the asymptomatic and presymptomatic infectious individuals - $\tau_A$ and $\tau_P$ respectively - are increased and the $\tau_I$ is kept at the baseline value for the U.S., the number of cumulative deaths decreases by about 35% at the end of the period - see Figure 11. Thus, the decrease is more pronounced when the $\tau_A$ and $\tau_P$ are increased than when the $\tau_I$ is increased which indicates that the asymptomatic and presymptomatic have more impact. Figure 12 focuses on the difference in impact with 50% increase in testing and shows that the asmptomatic and

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

presymptomatic testing gives up to about four times as much percent decrease as the symptomatic.

We can also compare the effect of these type of testing scenarios for different states. For example, although Wisconsin and Florida had similar testing rates around 12/10/2020, we find that a 50% increase in $\tau_A$ and $\tau_P$, results in roughly a 20% decrease in cumulative deaths for Wisconsin compared to a 50% decrease in cumulative deaths for Florida - Figure 13. Note that the results for both states show the greater influence of the aysmptomatic and presymptomatic infectious.




Figure 11: The effect of an increase in testing of symptomatic individuals versus asymptomatic and presymptomatic individuals on the cumulative deaths in the US during postlockdown period 5/15 to 8/11.




Figure 12: The effect of a 50% increase in testing of asymptomatic and presymptomatic versus symptomatic on the cumulative deaths in the US during postlockdown period 5/28 to 8/11.




Figure 13: The effect of a 50 percent increase in testing of asymptomatic and presymptomatic (green curve) versus symptomatic (magenta curve) individuals on the cumulative deaths for Wisconsin and Florida.

### *4.3.4. Minimum testing needed*

In this section we consider the question concerning the minimum rate of testing/detection required to lower the control reproduction number, $\mathcal{R}_C$ below one. This question is more difficult to answer directly, but we can begin to get at an answer by again considering the effect of increasing testing. For example, for the entire U.S. from May 28 to Aug 11 (after lifting of lockdown) if the testing is ramped up to the rate of

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

0.2 for asymptomatic and presymptomatic - that is, if $\tau_A$ and $\tau_P$ are both set to 0.2, while $\tau_I = 0.25$, then the reproduction control number $\mathcal{R}_C$ is 0.9819 (so just below 1). If $\tau_A$ and $\tau_P$ are bumped above 0.2, for example to 0.25, while $\tau_I$ remains at 0.25, then $\mathcal{R}_C$ falls well below 1 - to 0.8858 - and the resulting decrease in cumulative deaths and daily cases is shown in Figure 14. To get a better appreciation of the impact of testing for asymptomatic and presymptomatic cases, note that if $\tau_A$ and $\tau_P$ are kept at their baseline fitted values, then $\tau_I$ must be increased to 1.7 to get $\mathcal{R}_C = 0.9119$. Of course, the challenge with all of these testing scenarios is that the testing of asymptomatic and presymptomatic individuals is more difficult since those individuals do not have symptoms, so in order to achieve these testing rates, widespread and frequent testing should be implemented.




Figure 14: The effect of an increase in $\tau_A$ and $\tau_P$

### *4.4. Forward Simulation of the Pandemic*

Natural herd immunity refers to the process by which enough of the population achieves immunity via natural recovery from the disease, so that the remaining population that is not immune also receives protection against the acquisition of the disease. The process involves a natural herd immunity threshold, that is, the minimum number of people required to achieve disease-acquired immunity. For a disease with a basic reproduction number of $\mathcal{R}_0$, the necessary minimum fraction of people who must achieve immunity can be given as $1 - 1/\mathcal{R}_0$. We simulate for both Wisconsin (a state which was considered an epicenter later in 2020) and the entire U.S., a scenario in which COVID-19 is allowed to run its natural course (with no implementation of any new control or mitigation strategies) until natural herd immunity is achieved . For both Wisconsin and the entire US, the number of deaths that occur before reaching the herd immunity threshold, is considerably high; thus, making the success of a natural herd immunity strategy for COVID-19 questionable (at the very least). For the state of Wisconsin, the number of deaths that occurs is approximately 450,000 and for the entire U.S., the number of deaths is more than 10 million - see Figure 15.




Figure 15: The number of deaths that will occur before natural herd immunity threshold is achieved for the state of Wisconsin and the entire US. The simulations are run starting on October 13.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

## 5. Discussion

From various perspectives, our analysis indicates that overall, the drivers of COVID-19 are the asymptomatic and presymptomatic infectious individuals. We see that if testing is increased, these asymptomatic and presymptomatic infectious have a greater impact than the symptomatic infectious; hence, widespread and frequent testing is key to controlling the spread of the disease. This is especially true after holiday periods and large gathering events which are often notorious for reduced and lax implementation of control and mitigation strategies such as social distancing. Thus, in the schools and workplaces, testing should be intentionally and systematically increased after such occurrences in order to control the silent transmission by the newly infectious individuals who do not (yet) have symptoms. Our simulations also show that although lockdown might be difficult in terms of economic impact, the benefit of even a short lockdown (2 weeks) in reducing deaths is considerable.

## 6. Appendix A

### *6.1. Tables of State Variables and Parameter Values*

| **State Variable** | **Description** |
|---|---|
| $S$ | Population of susceptible individuals |
| $E$ | Population of non-quarantined exposed individuals (infected but not showing symptoms and cannot transmit infection; newly-infected but not infectious) |
| $E_P$ | Population of presymptomatic (infectious) individuals |
| $I$ | Population of symptomatically-infectious individuals |
| $A$ | Population of asymptomatically-infectious individuals |
| $J$ | Population of self-isolated individuals |
| $H$ | Population of hospitalized individuals |
| $R$ | Population of recovered individuals |
| $C$ | Population of individuals in intensive care unit (ICU) |
| $D$ | Population of COVID-19 deceased individuals |

Table 3: State variables for the Model 1

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

| Parameter | Description | Range | Baseline value | References |
|---|---|---|---|---|
| $\beta_I$ | Effective contact rate for symptomatically-infectious individuals | Fitting | Fitting | Fitting |
| $\beta_A$ | Effective contact rate for asymptomatically-infectious individuals | Fitting | Fitting | Fitting |
| $\beta_P$ | Effective contact rate for presymptomatically-infections individuals | Fitting | Fitting | Fitting |
| $\epsilon_m$ | Efficacy of face masks to prevent transmission and acquisition of infection ($0 < \epsilon_m \leq 1$) | 0.4 –0.6 | 0.5 | [10] |
| $c_m$ | Compliance in face mask usage in the community ($0 < c_m \leq 1$) | 0.01-0.19 | per state | [10] |
| $\sigma_e$ | Progression rate from exposed ($E$) to presymptomatic infectious class ($E_P$) infectious class | 1/2.5 day$^{-1}$ | 1/2.5 day$^{-1}$ | [10] |
| $\sigma_P$ | Progression rate from presymptomatic infectious class ($E_P$) to asymptomatically infectious or symptomatically infectious | 1/2.5 day$^{-1}$ | 1/2.5 day$^{-1}$ | [10] |
| $r$ | Fraction of exposed individuals who show clinical symptoms at the end of the incubation period | 0.4 – 0.6 | 0.5 | [9, 6, 5] |
| $\tau_P$ | Rate at which presymptomatic infectious individuals self-isolate | Fitting | Fitting | Fitting |
| $\tau_I$ | Rate self-quarantined symptomatically-infectious humans self-isolate | 1 – 2.5 day$^{-1}$ | 2.5 day$^{-1}$ | [13, 4, 11, 8] |
| $\tau_A$ | Rate at which asymptomatically-infectious humans self-isolate | Fitting | Fitting | Fitting |
| $\gamma_I$ | Recovery rate for individuals in the $I$ class | 1/30 – 1/3 day$^{-1}$ | 1/7 day$^{-1}$ | [9, 6, 5] |
| $\gamma_A$ | Recovery rate for individuals in the $A$ class | 1/14 – 1/3 day$^{-1}$ | 1/7 day$^{-1}$ | [9, 6, 5] |
| $\gamma_J$ | Recovery rate for self-isolated individuals | 0.1 – 0.15 day$^{-1}$ | 1/8 day$^{-1}$ | [9] |
| $\gamma_H$ | Recovery rate for hospitalized patients | 1/30 – 1/3 day$^{-1}$ | 1/14 day$^{-1}$ | [9, 6, 5] |
| $\gamma_C$ | Recovery rate for ICU patients | 0.018 – 0.027 day$^{-1}$ | 0.0225 day$^{-1}$ | [9] |
| $\psi_H$ | Rate of ICU admission for hospitalized individuals | 0.02 – 0.1 day$^{-1}$ | 0.083 day$^{-1}$ | [9, 5] |
| $\alpha_I$ | Hospitalization rate for symptomatically-infectious individuals | 0.1595 - 0.2803 day$^{-1}$ | 0.2199 day$^{-1}$ | [6, 5] |
| $\alpha_A$ | Hospitalization rate for asymptomatically-infectious individuals | 0.2 – 0.3 day$^{-1}$ | 1/4 day$^{-1}$ | [9] |
| $\alpha_J$ | Hospitalization rate for self-isolated individuals | Fitting | Fitting | Fitting |
| $\delta_I$ | Disease-induced mortality rate for symptomatically-infectious individuals | 0.018 – 0.027 day$^{-1}$ | 0.0225 day$^{-1}$ | [5, 7, 9] |
| $\delta_A$ | Disease-induced mortality rate for asymptomatically-infectious individuals | 0.006 – 0.009 day$^{-1}$ | 0.0075 day$^{-1}$ | [5] |
| $\delta_H$ | Disease-induced mortality rate for hospitalized individuals | 0.001 – 0.1 day$^{-1}$ | 0.015 day$^{-1}$ | [6, 5, 7] |
| $\delta_C$ | Disease-induced mortality rate individuals in ICU | 0.018 – 0.027 day$^{-1}$ | 0.0225 day$^{-1}$ | [6, 5] |

Table 4: **Parameter notation, description, values and sources for the Model 1.** Some values change depending on the state and time period.

### *6.2. Lockdown period with separated symptomatic and asymptomatic individuals*

In Figure 9, the results for the pre-lockdown and post-lockdown periods confirm the hypothesis that the asymptomatic and presymptomatic are the primary contributors to the spread of COVID-19. However, when we consider this scenario of targeting the asymptomatic and presymptomatic (by setting $\beta_I = 0$) versus the symptomatic (with $\beta_A = \beta_P = 0$) for lockdown, we get mixed results. In particular for New York and Wisconsin we get more symptomatic infectious cases than asymptomatic and presymptomatic - see Figure 16.




Figure 16: The plots show the daily cases for each state with $\beta_I = 0$ (cyan curve) and $\beta_A = \beta_P = 0$ (red curve) for the lockdown period.

### *6.3. Goodness of Fit*

In this section, we show the plots for the goodness of fit of the lockdown period for each state and the US as a whole.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .




Figure 17: US **Row 1**: Q-Q plots for the (1) Daily death values from the model (2) Daily death values from the data (3) Cumulative death values from the model (4) Cumulative death values from the data. **Row 2**: Box plot of the (1) Daily death values from the model and data (2) Cumulative death values from the model and data.




Figure 18: Florida **Row 1**: Q-Q plots for the (1) Daily death values from the model (2) Daily death values from the data (3) Cumulative death values from the model (4) Cumulative death values from the data. **Row 2**: Box plot of the (1) Daily death values from the model and data (2) Cumulative death values from the model and data.




Figure 19: Arizona **Row 1**: Q-Q plots for the (1) Daily death values from the model (2) Daily death values from the data (3) Cumulative death values from the model (4) Cumulative death values from the data. **Row 2**: Box plot of the (1) Daily death values from the model and data (2) Cumulative death values from the model and data.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .




Figure 20: New York **Row 1**: Q-Q plots for the (1) Daily death values from the model (2) Daily death values from the data (3) Cumulative death values from the model (4) Cumulative death values from the data. **Row 2**: Box plot of the (1) Daily death values from the model and data (2) Cumulative death values from the model and data.




Figure 21: Wisconsin **Row 1**: Q-Q plots for the (1) Daily death values from the model (2) Daily death values from the data (3) Cumulative death values from the model (4) Cumulative death values from the data. **Row 2**: Box plot of the (1) Daily death values from the model and data (2) Cumulative death values from the model and data.

## Acknowledgements

The authors thank MSRI and the AJOINT program for their continued support.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.28.20248967; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

## References

[1] Coronavirus. https://www.cdc.gov/coronavirus/2019-84ncov/hcp/planning-scenarios.html. Accessed: 2020-12-10.

[2] Covid-19 dashboard by the center for systems science and engineering. https://coronavirus.jhu.edu/map.html. Accessed: 2020-12-10.

[3] Covid-19 statistics. https://covid19.healthdata.org/united-states-of-america?view=mask-use&tab=trendl. Accessed: 2020-12-10.

[4] Gerardo Chowell, Diego Chowell, Kimberlyn Roosa, Ranu Dhillon, and Devabhaktuni Srikrishna. Sustainable social distancing through facemask use and testing during the covid-19 pandemic. *medRxiv*, pages 2020.04.01.20049981–2020.04.01.20049981, 2020.

[5] Steffen E. Eikenberry, Marina Mancuso, Enahoro Iboi, Tin Phan, Keenan Eikenberry, Yang Kuang, Eric Kostelich, and Abba B. Gumel. To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the covid-19 pandemic. *Infectious Disease Modelling*, 5:293–308, 2020.

[6] Abba B. Gumel, Enahoro Iboi, and Calistus N. Ngonghala. Using mathematics to understand covid-19 dynamics. *Notices of the American Mathematical Society*, (Under review), 2020.

[7] Enahoro Amos Iboi, Calistus N. Ngonghala, and Abba B Gumel. Will an imperfect vaccine curtail the covid-19 pandemic in the u.s.? *medRxiv*, page 2020.05.10.20097428, 01 2020.

[8] Adam J Kucharski and et al. Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of sars-cov-2 in different settings: a mathematical modelling study. *The Lancet Infectious Diseases*, 06 2020.

[9] Calistus N. Ngonghala, Enahoro Iboi, Steffen Eikenberry, Matthew Scotch, Chandini Raina MacIntyre, Matthew H. Bonds, and Abba B. Gumel. Mathematical assessment of the impact of non-pharmaceutical interventions on curtailing the 2019 novel coronavirus. *Mathematical Biosciences*, 325:108364, 2020.

[10] N. Iboi Enahoro A. Gumel Abba B. Ngonghala, Calistus. Could masks curtail the post-lockdown resurgence of COVID-19 in the US? *Mathematical Biosciences*, 329:1–18, 2020.

[11] Timothy P Sheahan and et al. An orally bioavailable broad-spectrum antiviral inhibits sars-cov-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. *Science Translational Medicine*, 12(541):eabb5883–eabb5883, 04 2020.

[12] P. van den Driessche and J. Watmough. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. *Mathematical Biosciences*, pages 29–48.

[13] Lee Worden, Rae Wannier, Seth Blumberg, Alex Y. Ge, George W. Rutherford, and Travis C. Porco. Estimation of effects of contact tracing and mask adoption on covid-19 transmission in san francisco: a modeling study. *medRxiv*, pages 2020.06.09.20125831–2020.06.09.20125831, 2020.




Ian M Mackay for virologydownunder.com
Created: 10MAR2020




$$\lambda = (1 - \epsilon_m c_m)\left(\beta_I I + \beta_A A + \beta_P E_P\right)\frac{1}{N}$$


Wisconsin Lockdown
Data
Model
Cumulative Deaths
3/25 - 5/26
0
100
200
300
400
500
600
20
30
40
50
60
70
80
90


Arizona Lockdown
Data
Fit
Cumulative Deaths
0
100
200
300
400
500
600
30
35
40
45
50
55
60
65
70
75
80
3/31 - 5/15


Florida Lockdown
Data
Model
Cumulative Deaths
1500
1000
500
0
35
40
45
50
55
60
65
4/3 - 5/4


New York Lockdown
Data
Model
0
0.5
1
1.5
2
2.5
3
3.5
20
30
40
50
60
70
80
90


Florida Lockdown
Data
Model
Cumulative Deaths
3/28 - 5/4
0
200
400
600
800
1000
1200
1400
25
30
35
40
45
50
55
60
65


New York Lockdown
Data
Model
0
0.5
1
1.5
2
2.5
3
0
10
20
30
40
50
60
70
80
90


New York Lockdown
Data
Model
0
0.5
1
1.5
2
2.5
3
3.5
10
20
30
40
50
60
70
80
90


Wisconsin Lockdown
Data
Model
Cumulative Deaths
3/11 - 5/26
0
100
200
300
400
500
600
10
20
30
40
50
60
70
80
90


Wisconsin Lockdown
Data
Model
Cumulative Deaths
3/18 - 5/26
0
100
200
300
400
500
600
10
20
30
40
50
60
70
80
90


Arizona Lockdown
Model
0
100
200
300
400
500
600
10
20
30
40
50
60
70
80


Arizona Lockdown
Data
0
100
200
300
400
500
600
20
30
40
50
60
70
80


Florida Lockdown
Data
Model
Cumulative Deaths
3/21 - 5/4
0
200
400
600
800
1000
1200
1400
20
25
30
35
40
45
50
55
60
65


Arizona Lockdown
Symptomatic
Infected
3/24 - 5/15


US Lockdown
Asymptomatic & Presymptomatic
Population
0
1000
2000
3000
4000
5000
6000
7000
8000
20
30
40
50
60
70
80
90
7/24 - 5/28


US Lockdown
Asymptomatic & Presymptomatic
Population
1/31 - 5/28


Arizona Lockdown
Symptomatic


New York Lockdown
Data
Fcast
0
0.5
1
1.5
2
2.5
3
3.5
20
30
40
50
60
70
80
90
100
110
120


New York Lockdown
Data
Model
0
0.5
1
1.5
2
2.5
3
3.5
20
30
40
50
60
70
80
90
100
110


Florida Lockdown
Data
Model
Cumulative Deaths
2500
2000
1500
1000
500
0
30
40
50
60
70
80
90
100
4/3 - 6/1


Florida Lockdown
Data
Model
Cumulative Deaths
4/3 - 5/18
0
200
400
600
800
1000
1200
1400
1600
1800
2000
35
40
45
50
55
60
65
70
75
80


Arizona Lockdown
Data
Model
1000
400
0
30
40
50
60
70
80
90
100
110


Arizona Lockdown
Data
Model
0
100
200
300
400
500
600
700
800
900
30
40
50
60
70
80
90
3/31 - 5/29


Wisconsin Lockdown
Data
Model
Cumulative Deaths
3/25 - 6/23
0
100
200
300
400
500
600
700
800
20
40
60
80
100
120


Wisconsin Lockdown
Data
Model
Cumulative Deaths
3/25 - 6/9
0
100
200
300
400
500
600
700
20
30
40
50
60
70
80
90
100
110


US Postlockdown
×10^5
4.8
4.6
4.4
4.2
4
3.8
3.6
3.4
3.2
3
2.8
Cumulative Deaths
without lockdown
with lockdown
280
285
290
295
300
305
310
315
320
325
330
Dec 07, 2020 - Jan 20, 2021


Arizona Post-Lockdown
Asymptomatic & Presymptomatic
Symptomatic
1200
400
0
70
80
90
100
110
120
130
140
150
160
170


Arizona Lockdown
Asymptomatic & Presymptomatic
Symptomatic
Population
3/31 - 5/15


Florida Post-Lockdown
Asymptomatic & Presymptomatic
Symptomatic
Population
5/4 - 8/11
0
1000
2000
3000
4000
5000
6000
7000
8000
60
80
100
120
140
160
180


Florida Lockdown
Asymptomatic & Presymptomatic
Symptomatic
Population
900
800
700
600
500
400
300
200
100
35
40
45
50
55
60
65
4/3 - 5/4


New York Lockdown
Asymptomatic & Presymptomatic
Population
0
1000
2000
3000
4000
5000
30
40
50
60
70
80
90


New York Post-Lockdown
Asymptomatic & Presymptomatic
1200
400
0
90
100
110
120
130
140
150
160
170


Wisconsin Lockdown
Asymptomatic & Presymptomatic
Symptomatic
Population
110
100
90
80
70
60
50
40
30
20
10
20
30
40
50
60
70
80
90
3/25 - 5/26


Wisconsin Post-Lockdown
Asymptomatic & Presymptomatic
Symptomatic
Population
200
180
160
140
120
100
80
60
40
80
90
100
110
120
130
140
150
160
170
5/26 - 8/11


New York Pre-Lockdown
Asymptomatic & Presymptomatic
3000
2000
1000
100
0
2
4
6
8
10
12
14
16
18
20
22


Florida Pre-Lockdown
Asymptomatic & Presymptomatic
Symptomatic
Population
600
500
400
300
200
100
0
10
15
20
25
30
35
3/10 - 4/3


Arizona Pre-Lockdown
Asymptomatic & Presymptomatic
Symptomatic
Percentage
0
10
20
30
40
50
60
70
80
90
100
20
22
24
26
28
30
32
3/21 - 3/31


Wisconsin Pre-Lockdown
Asymptomatic & Presymptomatic
Symptomatic
Population
3/19 - 3/25
0
10
20
30
40
50
60
70
19
20
21
22
23
24
25


Florida Post-Lockdown
Asymptomatic & Presymptomatic
Symptomatic
Population
5/4 - 8/11
3000
2500
2000
1500
1000
500
0
60
80
100
120
140
160
180


New York Pre-Lockdown
Asymptomatic & Presymptomatic
0
20
40
60
80
100
2
4
6
8
10
12
14
16
18
20
22


New York Post-Lockdown
1200
400
0
90
100
110
120
130
140
150
160
170


Wisconsin Pre-lockdown
Asymptomatic & Presymptomatic
Symptomatic
Population
0
10
20
30
40
50
60
19
20
21
22
23
24
25
3/19 - 3/25


Wisconsin Post-lockdown
Asymptomatic & Presymptomatic
Symptomatic
Population
200
180
160
140
120
100
80
60
40
20
0
80
90
100
110
120
130
140
150
160
170
5/26 - 8/11


Arizona Pre-Lockdown
Asymptomatic & Presymptomatic
Symptomatic
Percentage
3/21 - 3/31
0
10
20
30
40
50
60
70
80
90
100
20
22
24
26
28
30
32


Arizona Post-Lockdown
Symptomatic
Proportion
500
400
300
200
100
0
-100
70
80
90
100
110
120
130
140
150
160
170


Florida Pre-Lockdown
Asymptomatic & Presymptomatic
Symptomatic
Population
3/10 - 4/3
0
2
4
6
8
10
12
14
16
18
10
15
20
25
30
35


US Lockdown
Case 1
Case 2


Arizona Lockdown
Case 2
0
500
4000
3500
3000
30
35
40
45
50
55
60
65
70
75
80


Arizona Lockdown
Total
Case 1
Case 2
0
100
200
300
400
500
30
35
40
45
50
55
60
65
70
75
80


US Lockdown
Case 2
0
1
2
3
4
5
6
7
8
9
10
30
40
50
60
70
80
90


Effect of Percent Increase in TauG & TauP in US
Data
200%
1.6
1.5
1.4
1.3
1.2
1.1
1
90
100
110
120
130
140
150
160
170


Effect of Percent Increase in Tau1 in US
Data
20%


Effect of 50 Percent Increase in testing and isolating in FL
Data
tauA & tauP at 50% increase
taul 50% increase
Cumulative Deaths
5/04 - 8/11
9000
8000
7000
6000
5000
4000
3000
2000
1000
60
80
100
120
140
160
180


Effect of 50 Percent Increase in testing and isolating in WI
Data
tauA & tauP at 50% increase
taul 50% increase
Cumulative Deaths
5/26 - 8/11
1100
1000
900
800
700
600
500
80
90
100
110
120
130
140
150
160
170


Effect of 50 Percent Increase in testing and Isolating in US
Total 50% Increase
1.6
1.5
1.4
1.3
1.2
1.1
1
90
100
110
120
130
140
150
160
170


US , $R_0$= 5.5236 $R_c$= 3.624 enddate 47
×10^6
12
10
8
6
4
2
0
Cumulative Deaths
betaI=1.3 betaA=0.775 betaP=1.35
enddate 47 = Nov 29
0
5
10
15
20
25
30
35
40
45
50
10/13/2020 startdate


WI , $R_0$ = 3.0223 $R_c$= 2.4467 enddate 53
betaI = 0.117 betaA = 0.1018 betaP = 1.1166
enddate 53 = Dec 05
Cumulative Deaths
×10^5
5
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
0
10
20
30
40
50
60
10/13/2020 startdate


US Postlockdown
0
0.5
1
1.5
2
2.5
90
100
110
120
130
140
150
160
170


US, taul = tauA = tauP = 0.25
data
1.7
1.6
1.5
1.4
1.3
1.2
1.1
1
90
100
110
120
130
140
150
160
170


New York Lockdown
Asymptomatic & Presymptomatic
3000
2000
1000
100
0
30
40
50
60
70
80
90


Wisconsin Lockdown
Asymptomatic & Presymptomatic
Symptomatic
Population
3/25 - 5/26
0
10
20
30
40
50
60
70
80
90
100
20
30
40
50
60
70
80
90


Arizona Lockdown
Asymptomatic & Presymptomatic
Percentage
0
10
20
30
40
50
60
70
80
90
100
30
35
40
45
50
55
60
65
70
75
80


Florida Lockdown
Asymptomatic & Presymptomatic
Symptomatic
Population
900
800
700
600
500
400
300
200
100
0
35
40
45
50
55
60
65
4/3 - 5/4


Arizona Daily Deaths
0
10
20
Model
Data










Arizona Cumulative Deaths
400
200
0
Model
Data






Florida Cumulative Deaths
Model
Data


Florida Daily Deaths
Model
Data










New York State Cumulative Deaths
0
15000
30000
45000
Model
Data


New York Daily Deaths
1500
900
400
Model
Data












US Cumulative Deaths
0
22300
44600
Model
Data


US Daily Deaths
2000
1500
Model
Data










Wisconsin Cumulative Deaths
800
500
100
Model
CMU


Wisconsin Daily Deaths
Model
Data